Origenis GmbH. (5/28/24). "Press Release: OncoBone Ventures and Origenis Announce Partnership to Develop Novel Therapies for Cancer Bone Metastasis". Tübingen & Boston, MA.

	Product	AI-based drug discovery / AI-based drug development
	Product 2	cancer drug

OncoBone Ventures Ltd, based in the UK, and Origenis GmbH, headquartered in Planegg, Germany, have signed a Framework Agreement to develop novel therapies targeJng cancer bone metastasis, addressing a significant unmet medical need. Currently, there are no effecJve treatments for bone metastases, which affect 70-90% of advanced breast and prostate cancer paJents, with less than 5% surviving beyond five years post-diagnosis.

Origenis leverages its cuUng-edge ArJficial Intelligence (AI) driven technology plaYorm MolMind®·MOREsystem®·BRAINstorm™ to design innovaJve targeted small-molecule therapies. This technology plaYorm addresses and opJmizes highly specific distribuJon properJes of drug candidates to selected target Jssues of interest like bone, brain, and eye. Origenis has developed preclinical assets that have shown promising anJ-metastaJc potenJal in iniJal animal studies.

OncoBone Ventures is at the forefront of developing therapies for cancer bone metastasis using its proprietary osteoimmuno-oncology© (OIO) concept and preclinical Bone Metastasis Technology PlaYorm©, a clinically predicJve tool for evaluaJng the efficacy of therapeuJc candidates against bone metastases.

"We are very impressed with the AI-driven technology pla9orm of Origenis, and we are excited to partner with Origenis to evaluate the preclinical efficacy of their outstanding assets on bone metastases," said Jussi Halleen, CEO of OncoBone Ventures and conDnued, "Together, we have a high probability of success in advancing these assets towards clinical development."

Michael Thormann, CEO of Origenis, added, "We are delighted to collaborate with OncoBone Ventures, whose deep experEse in the bone metastasis field will maximize the likelihood of success in addressing this challenging unmet medical need. This strategic partnership is crucial to effecEvely advance the development of our novel small-molecule assets for bone metastasis."

For further informaDon, please contact:

OncoBone Ventures Ltd
Dr. Jussi Halleen, CEO
[email protected]
+358 45 263 7714

Origenis GmbH
Dr. Michael Thormann, CEO
[email protected]
+49 89 7801 676 110
www.origenis.de

Record changed: 2024-06-05

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)